Hemophilia & HAE Management Service
Out of the $3.5 trillion spent on healthcare, it is estimated that 25% is attributed to waste. With rare diseases like hemophilia and HAE, that number adds up quickly - representing up to a $1.5 billion opportunity for healthcare payers in the US.
This opportunity cannot be realized by monitoring claims data alone, high quality clinical data is necessary to add context and see the complete picture.
Audaire Health’s HIPAA compliant web platform provides the payer with 100% transparency on physician, pharmacy and patient performance.
The platform provides payers with unprecedented visibility into the hemophilia & HAE benefits. By combining physician and pharmacy performance data with patient utilization data, you can pinpoint areas for improvement to easily contain costs.
Payers can contain costs through validation of:
60 KG patient on Kovaltry, 3000 IU QOD:
Audaire Health has found that 50% of hemophilia factor patients have dosing and dispensing anomalies. This equates to an extra cost of $43,600 per patient.
What could your savings be?